Literature DB >> 18947658

Effects of hormonal treatment on the contralateral descended testis in unilateral cryptorchidism.

D Zivkovic1, D G Bica, F Hadziselimovic.   

Abstract

OBJECTIVE: One of the therapeutic options in the treatment of cryptorchidism is hormonal therapy with luteinizing hormone releasing hormone (LHRH) and/or human chorionic gonadotropin (HCG); concerns have, however, been raised regarding its safety. The purpose of this study was to demonstrate that hormonal therapy improves the abnormal histology of the contralateral descended testis without harming the germ cells.
METHOD: Patients with unilateral cryptorchidism were randomized into two groups: those treated with orchiopexy alone and those treated with LHRH long acting analog and HCG. Biopsies taken from contralateral descended testes were analyzed and compared with controls.
RESULTS: The number of germ cells per tubule in contralateral testes of patients treated with orchiopexy alone is significantly lower than the number of germ cells in testes of patients with spontaneously descended testes (P<0.0001). Hormonal therapy did not have any adverse effect upon the histology of the contralateral testis, but in fact improved it. Seven weeks of hormonal therapy induced a rise in the number of germ cells per tubule (P<0.05). It was also beneficial for the number of adult dark spermatogonia per tubule and the number of primary spermatocytes, although these differences did not reach statistical significance.
CONCLUSION: The contralateral testis in patients with unilateral cryptorchidism is abnormal. Hormonal therapy improves the histopathology of the contralateral testis without harming the germ cells.

Entities:  

Year:  2006        PMID: 18947658     DOI: 10.1016/j.jpurol.2005.11.007

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  8 in total

Review 1.  Fertility potential after unilateral and bilateral orchidopexy for cryptorchidism.

Authors:  Bojan Trsinar; Ursula Res Muravec
Journal:  World J Urol       Date:  2009-04-08       Impact factor: 4.226

2.  Effects on normalized testicular atrophy index (TAIn) in cryptorchid infants treated with GnRHa pre and post-operative vs surgery alone: a prospective randomized trial and long-term follow-up on 62 cases.

Authors:  Claudio Spinelli; Silvia Strambi; Marga Busetto; Valentina Pucci; Francesco Bianco
Journal:  Pediatr Surg Int       Date:  2014-08-09       Impact factor: 1.827

Review 3.  Undescended testicle: An update on fertility in cryptorchid men.

Authors:  Prabudh Goel; J D Rawat; A Wakhlu; S N Kureel
Journal:  Indian J Med Res       Date:  2015-02       Impact factor: 2.375

Review 4.  On the descent of the epididymo-testicular unit, cryptorchidism, and prevention of infertility.

Authors:  Faruk Hadziselimovic
Journal:  Basic Clin Androl       Date:  2017-11-14

5.  Selecting Infants With Cryptorchidism and High Risk of Infertility for Optional Adjuvant Hormonal Therapy and Cryopreservation of Germ Cells: Experience From a Pilot Study.

Authors:  Jorgen Thorup; Erik Clasen-Linde; Lihua Dong; Simone Hildorf; Stine Gry Kristensen; Claus Yding Andersen; Dina Cortes
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-05       Impact factor: 5.555

6.  Role of Ozone Therapy in Preventing Testicular Damage in an Experimental Cryptorchid Rat Model.

Authors:  Şenol Biçer; Cebrail Gürsul; İlyas Sayar; Orhan Akman; Seçil Çakarlı; Merve Aydın
Journal:  Med Sci Monit       Date:  2018-08-21

7.  PRDM Histone Methyltransferase mRNA Levels Increase in Response to Curative Hormone Treatment for Cryptorchidism-Dependent Male Infertility.

Authors:  Faruk Hadziselimovic; Gieri Cathomas; Gilvydas Verkauskas; Darius Dasevicius; Michael B Stadler
Journal:  Genes (Basel)       Date:  2018-08-01       Impact factor: 4.096

Review 8.  Fertility of Cryptorchid Testis-An Unsolved Mistery.

Authors:  Carmen Iulia Ciongradi; Ioan Sârbu; Codruța Olimpiada Iliescu Halițchi; Diana Benchia; Klara Sârbu
Journal:  Genes (Basel)       Date:  2021-11-26       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.